Premium
Fluvoxamine is ineffective in the treatment of enuresis in children and adolescents: an open‐label pilot study
Author(s) -
Toren Paz,
Eldar Sofia,
Laor Nathaniel,
Wolmer Leo,
Samuel Eliahu,
Weizman Ronit
Publication year - 2001
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.301
Subject(s) - fluvoxamine , enuresis , clomipramine , anticholinergic , serotonergic , psychology , tricyclic , medicine , anesthesia , psychiatry , fluoxetine , serotonin , pharmacology , receptor
Tricyclic antidepressants possess established antienuretic properties. The selective serotonin reuptake inhibitors (SSRIs) have similar antidepressant properties to the tricyclic antidepressants and a safer side effect profile. The aim of the present study was to evaluate the antienuretic efficacy of one SSRI, fluvoxamine. Nine children aged 9 to 14 years with primary enuresis which was resistant to behavioral therapy participated in the study. All received fluvoxamine, 75–100 mg per day. In four, the enuresis was the only focus of clinical attention, and five received fluvoxamine for other primary indications. Enuresis was monitored daily, and mean voiding frequency was compared between three phases: baseline, on treatment and off treatment. Fluvoxamine had no statistically significant effect on enuresis. Fluvoxamine does not seem to possess significant antienuretic properties. We suggest that the combination of serotonergic with anticholinergic activity is a major factor in the antienuretic activity. In the treatment of children or adolescents with obsessive‐compulsive disorder and comorbid enuresis, clomipramine may be preferred over SSRIs. Copyright © 2001 John Wiley & Sons, Ltd.